October, 2024
October 2024
M T W T F S S
 123456
78910111213
14151617181920
21222324252627
28293031  
Most viewed in the last 7 days from JAMA Oncology
Apr 3, 2024, 06:05

Most viewed in the last 7 days from JAMA Oncology

JAMA Oncology shared a post on LinkedIn:

“Most viewed in the last 7 days from JAMA Oncology: Do patients with resectable NSCLC and tumor programmed cell death 1 ligand 1 levels less than 1% benefit from neoadjuvant chemo immunotherapy?”

Additional information.
Source: JAMA Oncology/LinkedIn